Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent.

Sanada, Fumihiro; Taniyama, Yoshiaki; Azuma, Junya; Yuka, Ikeda-Iwabe; Kanbara, Yasuhiro; Iwabayashi, Masaaki; Rakugi, Hiromi; Morishita, Ryuichi.

Afiliación

Sanada F; Department of Clinical Gene Therapy.
Taniyama Y; Department of Clinical Gene Therapy ; Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Azuma J; Department of Clinical Gene Therapy ; Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Yuka II; Department of Clinical Gene Therapy.
Kanbara Y; Department of Clinical Gene Therapy.
Iwabayashi M; Department of Clinical Gene Therapy.
Rakugi H; Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Morishita R; Department of Clinical Gene Therapy.

Immunol Endocr Metab Agents Med Chem ; 14(1): 32-39, 2014 Apr.

Article en En | MEDLINE | ID: mdl-26005508

Palabras clave

Clinical limb ischemia; fibroblast growth factor; gene therapy; hepatocyte growth factor; peripheral artery disease; therapeutic angiogenesis; vascular endothelial growth factor.